REGENXBIO Inc. (RGNX): Depreciation & Amortization
$15.62M
Year ended 2025-12-31
$15.37M
Trailing 12 months to 2026-06-30
+6.5%
3-year compound annual growth
+13.2%
5-year compound annual growth
n/m
10-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $15.62M | -3.7% | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | $16.21M | -6.4% | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | $17.32M | +34.2% | 2025-03-13, From 2023-01-01 |
| 2022-12-31 | $12.91M | +35.0% | 2025-03-13, From 2022-01-01 |
| 2021-12-31 | $9.56M | +13.8% | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | $8.41M | +17.5% | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | $7.15M | +79.6% | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $3.98M | +48.3% | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | $2.69M | +393.8% | 2020-02-26, From 2017-01-01 |
| 2016-12-31 | $544.0K | +580.0% | 2019-02-27, From 2016-01-01 |
| 2015-12-31 | $80.0K | n/a | 2018-03-06, From 2015-01-01 |
| 2014-12-31 | $0 | n/a | 2017-03-07, From 2014-01-01 |
| 2013-12-31 | $0 | n/a | 2016-03-03, From 2013-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $15.62M | -3.7% |
| Ginkgo Bioworks Holdings, Inc. (DNA) | 2025-12-31 | $58.99M | -6.4% |
| Beam Therapeutics Inc. (BEAM) | 2025-12-31 | $22.29M | +1.7% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $8.58M | -3.1% |
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | $2.12M | -58.1% |
| Agenus Inc (AGEN) | 2025-12-31 | $10.00M | -25.1% |
| ImmunityBio, Inc. (IBRX) | 2025-12-31 | $15.53M | -11.6% |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | $35.94M | -4.4% |
| Vericel Corp (VCEL) | 2025-12-31 | $11.54M | +109.7% |
Compare RGNX, DNA, BEAM, VXRT side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗